ARID1A and gastric cancer: The discovery of a link between ARID1A inactivation and PD-L1, TMB, MMR, TILs, and systemic inflammatory markers in GC raises the possibility that ARID1A deletion might serve as a predictive biomarker for ICBs therapy for GC.